Value profile for respiratory syncytial virus vaccines and monoclonal antibodies.

Autor: Fleming JA; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Ave Suite 200, Seattle, WA 98121, United States. Electronic address: jfleming@path.org., Baral R; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Ave Suite 200, Seattle, WA 98121, United States. Electronic address: rbaral@path.org., Higgins D; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Ave Suite 200, Seattle, WA 98121, United States. Electronic address: dhiggins@path.org., Khan S; Maternal, Newborn, Child Health and Nutrition, PATH, 2201 Westlake Ave Suite 200, Seattle, WA 98121, United States. Electronic address: sakhan@path.org., Kochar S; Global Healthcare Consulting and Department of Global Health, University of Washington, Hans Rosling Center, 3980 15th Ave NE, Seattle, WA 98105, United States. Electronic address: sonalikochhar@yahoo.co.in., Li Y; School of Public Health, Nanjing Medical University, No. 101 Longmian Avenue, Jiangning District, Nanjing, Jiangsu Province 211166, PR China. Electronic address: you.li@njmu.edu., Ortiz JR; Center for Vaccine Development and Global Health, University of Maryland School of Medicine, 685 West Baltimore Street, Baltimore, MD 21201-1509, United States. Electronic address: jortiz@som.umaryl., Cherian T; MMGH Consulting GmbH, Kuerbergstrasse 1, 8049 Zurich, Switzerland. Electronic address: cheriant@mmglobalhealth.org., Feikin D; Department of Immunization, Vaccines and Biologicals, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland. Electronic address: feikind@who.int., Jit M; London School of Hygiene & Tropical Medicine, University of London, Keppel St, London WC1E 7HT, United Kingdom. Electronic address: mark.jit@lshtm.ac., Karron RA; Center for Immunization Research, Johns Hopkins University, Department of International Health, 624 N. Broadway, Rm 117, Baltimore, MD 21205, United States. Electronic address: rkarron@jhu.edu., Limaye RJ; International Health, Johns Hopkins Bloomberg School of Public Health, 615 North Wolfe Street, Baltimore, MD 21205, United States. Electronic address: rlimaye@jhu.edu., Marshall C; Department of Immunization, Vaccines and Biologicals, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland. Electronic address: cmarshall@who.int., Munywoki PK; Center for Disease Control and Prevention, KEMRI Complex, Mbagathi Road off Mbagathi Way, PO Box 606-00621, Village Market, Nairobi, Kenya. Electronic address: oha6@cdc.gov., Nair H; Centre for Global Health, Usher Institute, University of Edinburgh, Edinburgh EH8 9AG, United Kingdom. Electronic address: harish.nair@ed.ac.uk., Newhouse LC; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Ave Suite 200, Seattle, WA 98121, United States. Electronic address: lnewhouse@path.org., Nyawanda BO; Kenya Medical Research Institute, Hospital Road, P.O. Box 1357, Kericho, Kenya. Electronic address: bnyawanda@kemricdc.org., Pecenka C; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Ave Suite 200, Seattle, WA 98121, United States. Electronic address: cpecenka@path.org., Regan K; Center for Vaccine Innovation and Access, PATH, 2201 Westlake Ave Suite 200, Seattle, WA 98121, United States. Electronic address: kregan@path.org., Srikantiah P; Bill & Melinda Gates Foundation, 500 5th Ave N, Seattle, WA 98109, United States. Electronic address: padmini.srikantiah@gatesfoundation.org., Wittenauer R; Department of Pharmacy, University of Washington, Health Sciences Building, 1956 NE Pacific St H362, Seattle, WA 98195, United States. Electronic address: rwitten1@uw.edu., Zar HJ; Department of Paediatrics & Child Health and SA-MRC Unit on Child & Adolescent Health, Red Cross Children's Hospital, University of Cape Town, Klipfontein Road, Rondebosch, Cape Town 7700, South Africa. Electronic address: heather.zar@uct.ac.za., Sparrow E; Department of Immunization, Vaccines and Biologicals, World Health Organization, Avenue Appia 20, 1211 Geneva 27, Switzerland. Electronic address: sparrowe@who.int.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2023 Nov 03; Vol. 41 Suppl 2, pp. S7-S40. Date of Electronic Publication: 2023 Jul 06.
DOI: 10.1016/j.vaccine.2022.09.081
Abstrakt: Respiratory syncytial virus (RSV) is the predominant cause of acute lower respiratory infection (ALRI) in young children worldwide, yet no licensed RSV vaccine exists to help prevent the millions of illnesses and hospitalizations and tens of thousands of young lives taken each year. Monoclonal antibody (mAb) prophylaxis exists for prevention of RSV in a small subset of very high-risk infants and young children, but the only currently licensed product is impractical, requiring multiple doses and expensive for the low-income settings where the RSV disease burden is greatest. A robust candidate pipeline exists to one day prevent RSV disease in infant and pediatric populations, and it focuses on two promising passive immunization approaches appropriate for low-income contexts: maternal RSV vaccines and long-acting infant mAbs. Licensure of one or more candidates is feasible over the next one to three years and, depending on final product characteristics, current economic models suggest both approaches are likely to be cost-effective. Strong coordination between maternal and child health programs and the Expanded Program on Immunization will be needed for effective, efficient, and equitable delivery of either intervention. This 'Vaccine Value Profile' (VVP) for RSV is intended to provide a high-level, holistic assessment of the information and data that are currently available to inform the potential public health, economic and societal value of pipeline vaccines and vaccine-like products. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public private partnerships and multi-lateral organizations, and in collaboration with stakeholders from the WHO headquarters. All contributors have extensive expertise on various elements of the RSV VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.
Competing Interests: Declaration of Competing Interest The authors JAF, RB, DH, SK, LCN, CP, KR, and ES report financial support from Bill & Melinda Gates Foundation; YL reports financial support from Wellcome Trust and a professional relationship with Pfizer; JRO reports a professional relationship with Pfizer, Moderna Therapeutics, and Seqirus Inc.; MJ is a guest editor for the Vaccine supplement on Value Profiles for Vaccines and Monoclonal antibodies for Priority Pathogens; RAK reports financial support from the United States National Institutes of Health, Bill & Melinda Gates Foundation, and a professional relationship with GSK Vaccines SRL; HN reports financial support from Pfizer, Innovative Health Initiative, Bill & Melinda Gates Foundation, and the World Health Organization and a professional relationship with Sanofi, GSK, Novavax Inc., Merck Sharp & Dohme UK Ltd., AbbVie Inc., Janssen Pharmaceuticals, and ReSViNET Foundation; RW reports financial support from PATH; and HJZ reports financial support from Bill & Melinda Gates Foundation, South African Medical Research Council, Pfizer, Merck & Co. Inc., AstraZeneca Pharmaceuticals LP and a professional relationship with Sanofi and the World Health Organization. All other authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. To mitigate the potential for undue influence from industrial manufacturers, the first/corresponding author and the last author, neither of whom have relevant conflicts of interest, were responsible for the final version of this manuscript.
(Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: